Rel­ma­da re­ports a PhI­II fail, blam­ing 'para­dox­i­cal' place­bo ef­fect — shares wiped

A Flori­da biotech at­tempt­ing to de­vel­op a rapid-act­ing an­ti­de­pres­sant ran face-first in­to a brick wall Thurs­day.

Rel­ma­da Ther­a­peu­tics re­port­ed a Phase III fail for its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER